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Abstract
Objectives. To examine whether gout is an independent risk factor for total joint replacement (TJR) and whether urate-
lowering treatment (ULT) reduces this risk.
Methods. Using the Taiwan National Health Insurance database and the UK Clinical Practice Research Datalink, 74 560
Taiwan patients and 34 505 UK patients with incident gout were identified and age and sex matched to people without
gout. Cox proportional hazards models and condition logistic regression were used to examine the risk of TJR in gout
patients and the association between cumulative defined daily dose (cDDD) of ULT and TJR.
Results. The prevalence rates of TJR in the patients at the time of diagnosis of gout and in people without gout were
1.16% vs 0.82% in Taiwan and 2.61% vs 1.76% in the UK. After a gout diagnosis, the incidence of TJR was higher in
the patients with gout compared with those without (3.23 vs 1.91 cases/1000 person-years in Taiwan and 6.87 vs
4.61 cases/1000 person-years in the UK), with adjusted HRs of 1.56 (95% CI 1.45, 1.68) in Taiwan and 1.14 (1.05,
1.22) in the UK. Compared with patients with gout with <28 cDDD ULT, the adjusted ORs for TJR were 0.89 (95%
CI 0.77, 1.03) for 2890 cDDD, 1.03 (0.85, 1.24) for 90180 cDDD and 1.12 (0.94, 1.34) for >180 cDDD ULT in Taiwan. In
the UK, the respective ORs were 1.09 (0.83, 1.42), 0.93 (0.68, 1.27) and 1.08 (0.94, 1.24).
Conclusion. This population-based study provides evidence from two nation populations that gout confers significant
TJR risk, which was not reduced by current ULT.
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Rheumatology key messages
. Gout patients have a higher risk of total hip and knee replacement at diagnosis.
. The incidence of total joint replacement after a gout diagnosis was higher than in those without gout.
. Current urate-lowering treatment did not reduce the risk of total joint replacement in gout patients.
Introduction
Clinically, gout is characterized by recurrent acute attacks
of synovitis, chronic arthritis, subcutaneous urate crystal
concretions (tophi) and an increased risk of urolithiasis [1].
It is also associated with higher mortality [2] and many co-
morbidities [38]. Gout results from chronic hyperuricae-
mia, which leads to the deposition of monosodium urate
(MSU) crystals, mainly in and around peripheral joints, that
can damage joints irreversibly. As with OA and other
arthropathies, gout may result in the need for total joint
replacement (TJR) to restore function and reduce pain.
Mechanistic explanations for the irreversible joint
damage associated with gout primarily focus on the inter-
action between MSU crystals and joint tissues, especially
cartilage, bone and synovium [911]. However, few stu-
dies have investigated the association between irrevers-
ible joint damage in gout, which may result in an increased
need for total hip replacement (THR) and total knee re-
placement (TKR). One previous study reported the co-
localization of joints affected by acute attacks of gout
and OA [12], and we recently examined the risk of
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co-morbidities associated with gout and found a higher
prevalence of OA in people with gout [13]. The positive
association between gout and OA, the single most import-
ant risk factor for TJR, could potentially lead to an
increased risk of TJR in patients with gout [14].
Effective urate-lowering treatment (ULT) reverses
hyperuricaemia [15] and may help dissolve away MSU
crystals, which theoretically may retard the progression
of joint damage and subsequently reduce the risk of TJR
in patients with gout. However, the current use of ULT is
suboptimal, with only a third of patients being prescribed
ULT, usually at a fixed dose without titration to a target
serum uric acid level [16]. This may contribute to an
increased occurrence of complicated gout [17]. In add-
ition, people with gout are exposed to hyperuricaemia
and subclinical MSU crystal deposition long before the
initial clinical presentation and diagnosis of the disease.
By the time people present clinically (usually with an acute
attack of gout) and are diagnosed, substantial irreversible
joint damage may have already occurred [1821].
Therefore it is possible that initiating ULT after the occur-
rence of symptomatic arthritis may be insufficient to
reduce the risk of TJR. To the best of our knowledge,
no previous study has examined the risk of TJR of the
knee or hip in patients with gout and the possible effect
of current ULT practice on the risk of TJR.
We therefore used two population-based health data-
bases, the Taiwan National Health Insurance (NHI) data-
base and the UK Clinical Practice Research Datalink
(CPRD) to test the hypotheses that people with gout are
at increased risk of joint damage and subsequent TJR and
that the current practice of ULT usage may retard the
progression of joint damage in people with gout.
We used a cohort study of patients with incident gout
and matched people without gout identified from the gen-
eral population of Taiwan and the UK to compare the risk
of TJR prior to and following diagnosis. In addition, we
used a nested casecontrol study within the incident
gout cohort to examine the effect of the prior use of ULT
on the risk of TJR.
Methods
Sources of data
This study was approved by the institutional review
boards of Chang Gung Memorial Hospital and data
holders of the Taiwan NHI database and the UK CPRD.
The NHI database contains clinical and demographic data
of the entire population of Taiwan generated from the rou-
tine clinical practices of primary, secondary and specialist
care since 1996. The database covers 29 million people,
both alive and deceased as of 2016. The data collected
include demographic information, medical diagnoses,
prescriptions, surgical and diagnostic procedures, refer-
rals, vaccinations, Chinese herbal medicine, pharmacy,
dental care and maternity care. The centralized health in-
surance scheme ensures a coverage rate of 99.5% and
uniform data recording. Diagnoses and procedures are re-
corded using the International Classification of Diseases,
9th revision (ICD-9) diagnosis and procedure codes.
The NHI database has been used for a wide variety of
clinical and epidemiological research, including the as-
sessment of disease burden, pharmaco-epidemiology,
genetic epidemiology and planning for health policy
[13, 14, 16, 22, 23]. Multiple studies have validated the
NHI database and, in general, the accuracy of the re-
corded diagnoses in this database is high [2429].
The CPRD is an anonymized longitudinal database from
UK general practices containing individual-level medical
records. It was initiated in 1987 and includes 14 million
individuals in the UK. This database records comprehen-
sive information on demographics, lifestyle factors, med-
ical diagnoses, results of investigations and examinations,
operations, consultations, referrals and prescribed medi-
cations. The diagnostic coding system in the CPRD is the
Read code. The database has been well validated for
many diagnoses [3033]. Patient consent was not
required per ethical approval by the institutional review
board because all data obtained from the Taiwan NHI
database and the UK CPRD were anonymized by the
data holder.
Study design
We conducted this matched cohort study to examine the
risk of TJR, including THR and TKR in patients with inci-
dent gout and people without any record of a diagnosis of
gout or prescription for ULT. We identified all incident gout
patients diagnosed in 2005 in the general population of
Taiwan from the main NHI database and identified people
without gout using a systematically random sample of one
million people from the general population in 2005
(Fig. 1A). This calendar year was chosen because we
wanted to have appropriate periods to examine the TJR
risk both prior to (19962005) and after the diagnosis of
gout (200513). The patients with incident gout had to
have at least one record of a diagnosis of gout (ICD-9
code: 274.x) and had prescriptions for ULT after the diag-
nosis of gout in 2005, no evidence of gout and no pre-
scriptions for ULT prior to the date of diagnosis (index
date) and at least 1 year of continuous registration in the
NHI programme prior to the index date. The validity of the
gout diagnosis has been performed in a previous study
that showed a sensitivity of 76% and specificity of 1.00
[26]. For the systematically random sample, we identified
at random one subject who had no record of gout and no
prescriptions for ULT per gout patient. People without
gout were matched individually in a 1:1 ratio to the pa-
tients with incident gout by year of birth (±1 year) and
gender. The same index date was assigned to each of
the matched unexposed subjects. As with the patients
with incident gout, the unexposed subjects had at least
1 year of active participation in the NHI programme prior
to the index date. They were followed up and censored at
the earliest date of the first recorded TJR, death, deregis-
tration from the NHI or the end date of the study
(31 December 2013). For those who had both THR and
TKR, their first record of TKR or THR was used for TJR.
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The identification of a TJR was based on hospital records
for the surgical procedure.
For the UK, we identified patients with a new diagnosis
of gout from 1997 to 2006 who had at least a 1 year con-
tinuous registration prior to the index date (Fig. 1B). To
ensure the data quality recorded by each general practi-
tioner (GP), only those registered with up-to-standard
practices were included. The Read codes used to identify
gout and ULT are listed in supplementary Table S1, avail-
able at Rheumatology online. This code list was de-
veloped by our research team as described in our
previous publications [13, 16, 34]. In addition, the validity
of a gout diagnosis in the CPRD has been performed pre-
viously. When compared with a retrospective chart
review, the recorded diagnosis of gout in the CPRD is
accurate in 90% of cases [33]. People without gout
included participants from up-to-standard practices be-
tween 1997 and 2006 who had at least 1 year of continu-
ous registration and no record of gout or any ULT use
prior to the index date. We matched the patients with
gout at a ratio of 1:1 to unexposed subjects by year of
birth (±2 years), gender, general practice, year of first con-
tinuous registration (±2 years) and year of transfer out
(±2 years) at the same CPRD practice. The index date
was defined as the initial date of diagnosis of gout in the
cases, with the same date applied to their matched unex-
posed subjects.
To examine the effect of ULT on TJR in the patients with
gout, we carried out a nested casecontrol study using
data from the incident gout cohorts for both the Taiwan
and UK populations. Incident cases of TJR were identified
during the follow-up and matched at a 1:4 ratio to people
without TJR by age, sex and year of gout diagnosis. The
index date of each TJR (first date of hospitalization for TJR
for the Taiwan cohort and the date of the first GP record of
TJR in the UK population) was allocated to the matched
unexposed subjects who had not undergone joint replace-
ment (Fig. 1C for the Taiwan population and Fig. 1D for the
UK population). The reason for matching the year of gout
diagnosis and the index date was to ensure that those with
and without TJR had the same duration of ULT exposure.
Separate analyses were conducted for THR and TKR.
FIG. 1 Flow chart of the study population
(A) Cohort study based on the Taiwan NHI database. (B) Cohort study based on the UK CPRD. (C) Nested casecontrol
study based on the Taiwan NHI database. (D) Nested casecontrol study based on the UK CPRD.
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Outcomes
The main outcome was TJR. In the Taiwan population,
ascertainment of TJR was based on inpatient records.
We used ICD-9 procedure codes to ascertain primary
TKR (815.1815.3) and THR (815.4815.5). In the UK
population, the ascertainment of TJR was based on GP
records. The Read codes used to identify TJR are shown
in supplementary Table S1, available at Rheumatology
online.
ULT
In Taiwan, both xanthine oxidase inhibitors (allopurinol
and febuxostat) and uricosuric agents (benzbromarone,
sulfinpyrazone and probenecid) are approved and reim-
bursed by the NHI. Therefore ULT was further classified
into xanthine oxidase inhibitors and uricosuric agents.
However, in general practice in the UK, allopurinol is the
only widely available ULT. Therefore, in the UK analysis,
we only analysed the use of allopurinol.
The cumulative defined daily dose (cDDD; the average
maintenance dose per day for a drug used for its primary
indication in adults) was used to define the prescribed
amount of ULT from the time of first diagnosis of gout to
the index date of TJR [35]. Since we have transformed
cumulative dose into the same units (DDDs), cumulative
doses of different ULTs can be summed. We categorized
exposure to ULT into four groups (<28, 2890, 91180
and >180 cDDD) to evaluate the doseresponse effect
between ULT use and TJR.
Confounding variables
We included confounding covariates that were likely to be
associated with the risk of TJR. These included age at
diagnosis of gout, gender, socio-economic status,
Charlson co-morbidity index [36], other co-morbidities
relevant to TJR (RA, OA, diabetes and hip fracture) and
medications (proton pump inhibitors, NSAIDs, vitamin D,
bisphosphonate, glucocorticoids, insulin, other hypogly-
caemic agents, anti-hypertensives, nitrates, lipid-lowering
agents and anticonvulsants). In the UK population, we
also adjusted for BMI, smoking status and alcohol
consumption.
Statistical analysis
The prevalence of TJR at the time of diagnosis of gout
was estimated in both the Taiwan and UK cohorts.
Multivariate conditional logistic regression was performed
to estimate odds ratios (ORs) and 95% CIs for TJR. The
KaplanMeier method was used to compute the cumula-
tive incidence of TJR after a gout diagnosis in the patients
with incident gout and matched unexposed subjects.
Unadjusted and adjusted hazard ratios (HRs) and 95%
CIs with adjustments for confounding variables were cal-
culated for the risk of TJR using a Cox proportional haz-
ards model. The results of the nested casecontrol study
for the effect of ULT on TJR are presented as OR (95% CI)
estimated by conditional logistic regression. We con-
ducted a sensitivity analysis by excluding people with
OA, RA or hip fractures prior to or at the diagnosis of
gout. All analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC, USA).
Results
Prevalence of TJR at the initial diagnosis of gout
compared with people without gout
As shown in Fig. 1A and B, we identified 74 560 patients
with gout and 74 560 matched subjects in the Taiwan
cohort and 34 505 patients with gout and 34 505 matched
unexposed subjects in the UK cohort. Table 1 shows the
characteristics of the patients with gout and their matched
unexposed subjects at diagnosis. The mean age at diag-
nosis of gout in the UK cohort [61.4 (S.D. 14.8) years] was
significantly older than that in the Taiwan cohort [48.8 (S.D.
16.4) years; P< 0.001]. The Taiwan cohort had a longer
observation period before a diagnosis of gout, however,
the median follow-up period was similar (8.5 vs 8.8 years).
In both cohorts the patients with incident gout tended to
have more co-morbidities with a significantly higher
Charlson co-morbidity index. Co-morbidities related to
TJR that were more common in the patients with gout
included diabetes and OA, and this was consistent in
both cohorts.
At the index date, the prevalence of TJR was signifi-
cantly higher in the patients with incident gout than in
people without gout (1.16 vs 0.82% in the Taiwan cohort
and 2.61 vs 1.76% in the UK cohort). In the unadjusted
analysis, gout was associated with a statistically signifi-
cant increased risk of TJR in both Taiwan [OR 1.44 (95%
CI 1.29, 1.60)] and the UK [OR 1.50 (95% CI 1.35, 1.67)]
(supplementary Table S2, available at Rheumatology
online). After adjusting for covariates, the association be-
tween gout and TJR at diagnosis was still statistically sig-
nificant [adjusted OR in Taiwan 1.21 (95% CI 1.09, 1.35);
adjusted OR in the UK 1.21 (95% CI 1.07, 1.37)].
Incidence of TJR after a diagnosis of gout compared
with the people without gout
Overall there were 1898 incident cases of TJR in the
Taiwan cohort and 1906 cases in the UK cohort. The in-
cidence of TJR was higher in the gout group than in un-
exposed subjects in both the Taiwan (3.23 vs 1.91/1000
person-years) and UK (6.87 vs 4.61/1000 person-years)
cohorts. Fig. 2 shows the cumulative incidence of THR
and TKR in both the Taiwan and UK cohorts. Crude risk
estimates for THR, TKR and TJR were significantly higher
in the gout group compared with people without gout. The
unadjusted HR for TJR was 1.70 (95% CI 1.58, 1.83) in the
Taiwan cohort and 1.49 (95% CI 1.38, 1.60) in the UK
cohort. After adjusting for covariates, the HR was 1.56
(95% CI 1.45, 1.68) for TJR in the Taiwan cohort and
1.14 (95% CI 1.05, 1.22) in the UK cohort. The HRs and
95% CIs for THR and TJR are presented in Table 2.
Association between ULT and risk of TJR in the
patients with gout
Table 3 shows the associations between cDDDs of ULT
and TJR in both cohorts. Compared with the patients with
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TABLE 1 Demographic and co-morbid characteristics of the Taiwan and UK cohorts
Characteristics
Taiwan cohort UK cohort
Gout cases
(n=74 560)
People
without gout
(n=74 560) P-value
Gout cases
(n=34 505)
People
without gout
(n=34 505) P-value
Age, mean (S.D.), years 48.8 (16.4) 48.8 (16.4) NA 61.4 (14.8) 61.1 (14.8) NA
Male, n (%) 54 583 (73.21) 54 583 (73.21) NA 25 410 (73.64) 25 410 (73.64) NA
Observation years, median (IQR)
Prior to index date 10.3 (10.010.5) 10.3 (10.010.5) 0.277 5.7 (3.19.3) 5.6 (2.99.3) <0.001
After index date 8.5 (8.28.7) 8.5 (8.28.7) <0.001 8.8 (4.911.6) 8.8 (4.811.7) <0.001
CCI scores, n (%)
Mean (S.D.) 0.28 (0.74) 0.22 (0.71) <0.001 0.32 (0.75) 0.19 (0.57) <0.001
0 60 774 (81.51) 63 913 (85.72) <0.001 27 038 (78.36) 29 717 (86.12) <0.001
1 9283 (12.45) 7036 (9.44) 4939 (14.31) 3425 (9.92)
52 4503 (6.04) 3611 (4.84) 2528 (7.33) 1363 (3.95)
Co-morbidities, n (%)
RA 99 (0.13) 157 (0.21) <0.001 108 (0.31) 139 (0.40) 0.048
Diabetes mellitus 5297 (7.10) 4504 (6.04) <0.001 2295 (6.65) 1792 (5.19) <0.001
OA 5219 (7.00) 3134 (4.20) <0.001 1957 (5.67) 1319 (3.82) <0.001
Hip fracture 147 (0.20) 150 (0.20) 0.862 11 (0.03) 15 (0.04) 0.432
Co-medications, n (%)
Proton pump inhibitor 2523 (3.38) 1976 (2.65) <0.001 NA
NSAIDs 54 801 (73.50) 42 524 (57.03) <0.001 26 055 (75.5) 8498 (24.6) <0.001
Vitamin D 63 (0.08) 50 (0.07) 0.221 709 (2.1) 587 (1.7) <0.001
Bisphosphonate 155 (0.21) 187 (0.25) 0.083 720 (2.1) 713 (2.1) 0.852
Glucocorticoids 15 257 (20.46) 10 592 (14.21) <0.001 NA
Insulin 1097 (1.47) 847 (1.14) <0.001 429 (1.2) 427 (1.2) 0.945
Other hypoglycaemic agents 5299 (7.11) 4243 (5.69) <0.001 1596 (4.6) 1350 (3.9) <0.001
Anti-hypertensives 25 401 (34.07) 15 383 (20.63) <0.001 14 963 (43.4) 7674 (22.2) <0.001
Nitrates 3371 (4.52) 2159 (2.90) <0.001 4196 (12.2) 2266 (6.6) <0.001
Lipid-lowering agents 5222 (7.00) 3178 (4.26) <0.001 670 (1.9) 272 (0.8) <0.001
Anticonvulsants 2845 (3.82) 2218 (2.97) <0.001 691 (2.0) 706 (2.0) 0.685
Place of residence, n (%)
Urban 40 328 (54.09) 43 004 (57.68) <0.001 NA
Suburban 23 858 (32.00) 23 600 (31.65)
Rural 8194 (10.99) 6338 (8.50)
Unknown 2180 (2.92) 1618 (2.17)
Income level, n (%)
Quintile 1 15 499 (20.79) 15 627 (20.96) <0.001 NA
Quintile 2 5698 (7.64) 5599 (7.51)
Quintile 3 24 768 (33.22) 22 386 (30.02)
Quintile 4 14 783 (19.83) 15 086 (20.23)
Quintile 5 13 812 (18.52) 15 862 (21.27)
Occupationb, n (%)
1 13 746 (18.44) 14 094 (18.90) <0.001 NA
2 2625 (3.52) 3116 (4.18)
3 22 401 (30.04) 24 029 (32.23)
4 25 176 (33.77) 22 504 (30.18)
5 10 612 (14.23) 10 817 (14.51)
BMI, n (%), kg/m2
18.524.9 NA 6856 (19.9) 10 224 (29.6) <0.001
<18.5 223 (0.6) 512 (1.5)
25.029.9 13 739 (39.8) 11 126 (32.2)
530 11 094 (32.2) 5278 (15.3)
Unknown 2593 (7.5) 7365 (21.3)
Smoking, n (%)
Non-smoker NA 11 088 (32.1) 9064 (26.3) <0.001
Current smoker 9172 (26.6) 6514 (18.9)
Ex-smoker 10 869 (31.5) 11 117 (32.2)
Unknown 3376 (9.8) 7810 (22.6)
(continued)
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gout with a cDDD <28 for xanthine oxidase inhibitors,
cDDDs of 2890, 91180 and >180 were associated
with adjusted ORs for TJR of 1.06 (95% CI 0.83, 1.34),
1.02 (0.70, 1.50) and 1.25 (0.83, 1.88) in the Taiwan cohort
and 1.09 (0.83, 1.42), 0.93 (0.68, 1.27) and 1.08 (0.94,
1.24) in the UK cohort, but these estimates did not
reach statistical significance. We conducted further ana-
lyses of uricosuric agents in Taiwan only, as they were not
TABLE 1 Continued
Characteristics
Taiwan cohort UK cohort
Gout cases
(n=74 560)
People
without gout
(n=74 560) P-value
Gout cases
(n=34 505)
People
without gout
(n=34 505) P-value
Alcohol consumption, n (%), U/week
Never/ex-drinker NA 3368 (9.8) 3616 (10.5) <0.001
Current 19 13 963 (40.5) 13 750 (39.8)
Current 510 11 553 (33.5) 6931 (20.1)
Unknown 5621 (16.3) 10 208 (29.6)
CCI: Charlson co-morbidity index; NA: not available.
FIG. 2 The cumulative incidence of THR and TKR in patients with gout and without gout
(A) THR in Taiwan. (B) TKR in Taiwan. (C) THR in the UK. (D) TKR in the UK.
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available in the UK. Similarly, no association was found
between the use of uricosuric agents and the risk of TJR.
Sensitivity analysis
We conducted a sensitivity analysis by excluding people
with TJR, RA, OA and hip fractures prior to the initial diag-
nosis of gout. Comparisons of the risk of TJR at and after
a diagnosis of gout in both cohorts are shown in supple-
mentary Table S3, available at Rheumatology online.
Similar to the primary analysis, in general the patients
with gout had a higher risk of TJR at or after the initial
diagnosis compared with their matched unexposed sub-
jects. The results of nested casecontrol studies examin-
ing the impact of ULT on the risk of TJR were shown in
supplementary Table S4, available at Rheumatology
online. Similar to the primary analysis, ULT did not alter
the risk of TJR in the patients with gout in both countries.
Discussion
In this population-based study using data from the general
populations of Taiwan and the UK, we found that the risk
of TJR at both the hip and the knee was significantly
higher in patients with gout than in people without gout.
However, among the patients with gout, a higher dose of
current ULT was not associated with any reduction in the
risk of TJR after considering multiple factors including
socio-economic status, lifestyle and co-morbidities.
These results were consistent in both the Taiwan and
UK cohorts. To the best of our knowledge, this is the
first study to examine the risk of both THR and TKR con-
sidering a temporal relationship with an initial diagnosis of
gout and the impact of ULT on the risk of TJR in patients
with gout.
This study utilizes two nationwide databases that
enable an indirect comparison of TJR risks in gout pa-
tients. First, the average age of gout diagnosis is much
younger in Taiwan (49 years) than in the UK (61 years) and
both the crude TJR prevalence at diagnosis and the inci-
dence afterward in Taiwanese gout patients is approxi-
mately half that of the UK. The UK cohort therefore had
a higher ‘background’ TJR risk despite a numerically
lower relative risk. Previous studies have repeatedly docu-
mented a high incidence of gout in the young population in
Taiwan [37]. The reason is unclear, but Taiwanese abori-
ginals, who are genetically close to Pacific Islanders, are
one of the populations with the highest gout incidence in
the world [14]. Second, due to the limitation of covariate
availability, BMI was not adjusted for in the Taiwan cohort.
In the UK cohort, 32.2% of gout patients had a BMI
>30 kg/m2, which is much higher than in people without
gout. It is evident that adjustment in the UK results in a
greater attenuation of HR estimates, particularly for the
TKR risk. Therefore obesity at least partly contributes to
the risk of TJR. In general, Taiwanese tend to have a
smaller body size and less obesity. A nationwide
nutritional survey found the average adult BMI was
23.8 kg/m2 [38], but whether BMI affects TJR risk in
Taiwan needs further study. T
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Although gout has long been considered to be a minor
disease with negligible adverse long-term outcomes [39],
contemporary evidence supports an increased risk of
multiple co-morbidities and mortality in people with gout
[13]. MSU crystal deposition can cause mechanical and
inflammatory damage to tissues within and around joints
and clinically results in chronic usage-related pain, func-
tional impairment and radiographic structural changes of
OA in people with gout. Therefore gout is a potential risk
factor for TJR, although there is currently only limited evi-
dence regarding the risk of TJR in people with gout [40].
TJR is a major surgical procedure that is only undertaken
for ‘failed joints’ that are unresponsive to other interven-
tions. Therefore it can be considered a surrogate for irre-
versible and severe joint damage. Although the knee is a
known target joint for gout, hip involvement has been con-
sidered to be uncommon in acute attacks of gout [41],
even though silent MSU accumulation and consequent
joint damage is possible. This study supports the signifi-
cant effects of gout on both the knees and hips.
This study is based on nationwide databases in Taiwan
and the UK and the results showed that gout was a risk
factor for TJR, independent from OA and RA, the two
major causes of TJR, and other accepted risk factors.
The large difference between crude and adjusted risk
measures suggests that covariates associated with gout
are also significant risk factors for TJR. However, more
gout patients had undergone TJR at the time of a diagno-
sis of gout, suggesting that factors present before the first
attack of gout increased the risk of joint damage.
Moreover, the risk seemed to continue after gout had
been diagnosed. In this regard, hyperuricaemia occurs
in people with gout long before an initial clinical presen-
tation and diagnosis and continues in the absence of ad-
equate treatment. A recent study found that serum urate
levels were correlated with the degree of joint space nar-
rowing in the knees of people without gout [42]. Moreover,
synovial uric acid levels have been associated with the
severity of OA in patients with and without gout [43]. In
addition to hyperuricaemia, urate crystal deposition may
also predate the clinical presentation by a long period of
time, and occult joint damage from the mechanical and
chronic inflammatory effects of microtophi may already be
present at the time of the first clinical presentation [1821,
44]. Therefore effective ULT could potentially retard the
progression of joint damage and reduce the risk of TJR
both by reducing urate levels and by dissolving existing
crystals.
However, the current study found that the risk of both
THR and TKR was not reduced by the use of ULT follow-
ing a diagnosis of gout, and the results were consistent in
both the Taiwan and UK cohorts. In addition, the ORs for
TJR were not significant across a range of cumulative
doses of ULT, which suggests that ULT at commonly
used doses is not effective in alleviating progressive
joint damage and reducing TJR. Our recent study using
UK primary care data found that a diagnosis of gout was
associated with OA, with an OR of 1.27, and that following
the initial diagnosis of gout the HR for OA was 1.45 [13].
Therefore irreversible joint damage may occur before the
initial diagnosis of gout. Preclinical asymptomatic MSU
crystal deposition has been demonstrated in one-third of
TABLE 3 Nested casecontrol study to assess the association between ULT use and TJR among patients with gout
Use of uric
acid drugs
Taiwan cohort UK cohort
THR, adjusted
OR (95% CI)
TKR, adjusted
OR (95% CI)
TJR, adjusted
OR (95% CI)
THR, adjusted
OR (95% CI)
TKR, adjusted
OR (95% CI)
TJR, adjusted
OR (95% CI)
Xanthine oxidase inhibitors
<28 cDDD 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
28490 cDDD 1.03 (0.74, 1.44) 1.06 (0.75, 1.50) 1.06 (0.83, 1.34) 1.13 (0.82, 1.56) 0.93 (0.62, 1.40) 1.09 (0.83, 1.42)
914180 cDDD 0.92 (0.52, 1.62) 0.91 (0.54, 1.52) 1.02 (0.70, 1.50) 1.36 (0.92, 2.02) 0.69 (0.43, 1.11) 0.93 (0.68, 1.27)
>180 cDDD 1.27 (0.74, 2.20) 0.75 (0.43, 1.33) 1.25 (0.83, 1.88) 1.02 (0.85, 1.22) 1.01 (0.83, 1.22) 1.08 (0.94, 1.24)
P for trend 0.57 0.42 0.31 0.59 0.88 0.34
Uricosuric agentsa
<28 cDDD 1.00 (reference) 1.00 (reference) 1.00 (reference) NA NA NA
28490 cDDD 0.91 (0.73, 1.13) 0.97 (0.78, 1.20) 0.89 (0.77, 1.04) NA NA NA
914180 cDDD 0.98 (0.73, 1.30) 0.95 (0.70, 1.27) 1.00 (0.81, 1.23) NA NA NA
>180 cDDD 0.96 (0.73, 1.27) 1.16 (0.89, 1.52) 1.04 (0.86, 1.26) NA NA NA
P for trend 0.67 0.48 0.93 NA NA NA
Urate-lowering therapy
<28 cDDD 1.00 (reference) 1.00 (reference) 1.00 (reference) NA NA NA
28490 cDDD 0.89 (0.72, 1.10) 0.98 (0.79, 1.20) 0.89 (0.77, 1.03) NA NA NA
914180 cDDD 0.99 (0.76, 1.30) 1.03 (0.79, 1.35) 1.03 (0.85, 1.24) NA NA NA
>180 cDDD 1.04 (0.81, 1.33) 1.09 (0.85, 1.40) 1.12 (0.94, 1.34) NA NA NA
P for trend 0.91 0.53 0.36 NA NA NA
aORs and 95% CIs estimated by conditional logistic regression analysis and adjusted for socio-economic status, Charlson co-
morbidity index, co-morbidities and co-medications in the Taiwan cohort and Charlson co-morbidity index, BMI, smoking
status, alcohol consumption, co-morbidities and co-medications in the UK cohort. *P < 0.05.
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people with ‘asymptomatic’ hyperuricaemia [1821], and
extensive MSU crystal deposition can be seen on imaging
such as dual-energy computerized tomography at the
time of diagnosis of gout [44]. This prolonged preclinical
asymptomatic phase of gout that may associate with joint
damage is a relatively new concept, and a new staging
system for gout proposed in 2014 by Dalbeth and Stamp
[45] formally partitions the ‘asymptomatic’ spectrum into
asymptomatic hyperuricaemia (stage A) and MSU depos-
ition without signs or symptoms of gout (stage B).
The results of this study reflect the possible existence of
irreversible joint damage at the time of diagnosis of gout
and support the clinical relevance of the new staging
system. Therefore screening and treating asymptomatic
disease, particularly for patients with stage B (i.e. subclin-
ical gout), seems to be a rational approach, although in
most countries ULT is not licensed to treat hyperuricaemia
per se in the absence of gout or urolithiasis.
Currently there are no explicit evidence-based recom-
mendations concerning when in the clinical course of gout
patients should be considered for ULT. Current trends in-
creasingly favour early intervention with ULT, even around
the time of first diagnosis, to prevent further crystal de-
position and long-term complications such as subcutane-
ous tophi and joint damage, rather than waiting until these
have occurred [39]. This is indirectly supported by previ-
ous studies showing frequent attacks in untreated
patients [46] and a high prevalence of associated co-
morbidities such as chronic kidney disease [8, 47] and
urolithiasis. Our previous study using UK CPRD data
found that many co-morbidities, including OA, are more
frequently observed in patients at the time of diagnosis of
gout compared with matched people without gout, indi-
cating that damage occurred earlier than clinically appar-
ent gout [13]. The current study further demonstrates that
such existing joint damage may already be irreversible at
diagnosis. An alternative explanation for the lack of effect
of ULT in reducing the risk of TJR is that many people
prescribed ULT are not ‘treated to target’ by up-titration
of ULT against serial serum urate levels until a target level
below the saturation point for MSU crystal formation is
reached. More studies are needed to ascertain the pos-
sible beneficial effects of ULT prescribed according to
individualized ‘treat-to-target’ recommendations to
prevent joint damage in asymptomatic people with
hyperuricaemia.
Limitations
There are several limitations to this study. First, misclassi-
fication may exist since identification of patients with gout
was by physician-based diagnosis without requirement to
demonstrate urate crystal presence. In addition, the iden-
tification of joint replacement was based on procedure
codes, and only those who received the respective pro-
cedures could be coded for reimbursement purposes.
Currently both THR and TJR are subject to case payment
schemes that require application prior to surgery.
Therefore the case definition for joint replacement is
robust in the Taiwan NHI database. In the UK CPRD, the
recording of TJR has previously been validated [48].
Second, residual confounding may exist, for example,
with respect to BMI and physical activity in Taiwan.
Such information cannot be obtained from the NHI data-
base. However, we included BMI, alcohol and smoking in
the model using the UK cohort, and this yielded similar
results. Third, we only observed ULT prescriptions rather
than real patient consumption, and gout patients are
recognized to have possibly the worst adherence to
long-term medications of all patients with chronic ill-
nesses [39]. Fourth, the definition of doses was based
on cDDD, which is the accumulated ‘unit’ of daily
assumed average dose of ULT. Therefore our data reflect
the assumed average consumption of ULT as defined by
the World Health Organization. This definition cannot ac-
count for possible differences in hypouricaemic efficacy.
However, using this definition, it is feasible to compare
drug use between different drugs or between different
health care systems, such as in Taiwan and the UK.
Fifth, the serum uric acid levels were not available in the
Taiwan NHI database and were uncommonly and incon-
sistently recorded in the UK CPRD. Therefore we cannot
adjust hyperuricaemia as a covariate.
Conclusions
More gout patients already had joint replacements at the
time of diagnosis of gout than their matched unexposed
subjects, and after diagnosis the patients with gout con-
tinued to have a higher risk of both THR and TJR after
adjustment for OA. This suggests that chronic hyperuri-
caemia and asymptomatic MSU crystal deposition prior to
the first clinical presentation of gout may result in joint
damage. The current standard of ULT treatment after
diagnosis of gout did not to reduce this risk, and either
earlier interventions or more optimal treat-to-target use of
ULT, or both, may be required.
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